 |
|
|
| |
Safety of Once-Daily Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide in Participants With Glomerular Filtration Rate <50 mL/min: 48-Week Results
|
| |
| |
Reported by Jules Levin
ICAAC 2015 Sept 17-21 San Diego, CA
Samir K. Gupta,1 Frank Post,2 Anton Pozniak,3 James McMahon,4 Anchalee Avihingsanon,5
Jihad Slim,6 Robert Grossberg,7 Anne Khalsa,8 Joseph Custodio,9 Michael Abram,9
Xuelian Wei,9 Andrew Cheng,9 Scott McCallister,9 Marshall W. Fordyce9
1Indiana University School of Medicine, Indianapolis, IN; 2King's College Hospital NHS Foundation Trust, London, UK; 3Chelsea and Westminster Hospital NHS Foundation Trust, London; 4Burnet Institute, Melbourne, Australia; 5HIV-NAT, Thai Red Cross AIDS Research Center, Prathumwan, Thailand; 6Saint Michael's Medical Center, Newark, NJ; 7Center for Positive Living/ID Clinic, Montefiore Medical Center, Bronx, NY; 8Maricopa Integrated Health System-McDowell Clinic, Phoenix, AZ; 9Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
